Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The India cancer biomarkers market was valued at USD 1.25 Billion in 2025, driven by increasing prevalence of cancer across the region. The market is anticipated to grow at a CAGR of 6.00% during the forecast period of 2026-2035, with the values likely to reach USD 2.24 Billion by 2035. With high mortality rates in cancers like breast, cervical, and lung due to late diagnosis, there is an increasing demand for biomarker tests that enable early, accurate detection and personalized treatment strategies.
Key Market Trends and Insights
- The ‘Make in India’ initiative is driving the development and launch of locally manufactured, high-precision cancer biomarker kits, reducing dependency on imports and lowering costs for early cancer detection.
- Collaborations between Indian diagnostic firms and global technology leaders are facilitating advanced biomarker development and faster regulatory approvals, boosting the market’s technological capabilities.
- High tobacco consumption in India fuels the incidence of lung and oral cancers, creating urgent demand for specialized biomarker tests that support early diagnosis and effective management of these tobacco-associated cancers.
Market Size and Forecast
- Market Size in 2025: USD 1.25 Billion
- Projected Market Size in 2035: USD 2.24 Billion
- Compound Annual Growth Rate (CAGR) of 2026 to 2035: 6.00%
Compound Annual Growth Rate
6%
Value in USD Billion
2026-2035
India Cancer Biomarkers Market Overview
According to ICMR-National Institute of Cancer Prevention and Research, India is witnessing a growing cancer burden, with approximately 2.5 million people currently living with the disease. Each year, over 7 lakh new cancer cases are registered, and around 5.56 lakh cancer-related deaths are reported. The large and growing cancer-affected population creates a significant demand for advanced diagnostic tools. Biomarker-based tests enable early detection, risk assessment, and personalized treatment, which are crucial in improving patient outcomes. Given these factors, the cancer biomarkers market in India is poised for significant growth in the forecast period.
India Cancer Biomarkers Market Growth Drivers
Rise in Government Initiatives to Boost Market Growth
With a strong focus on prevention, early detection, treatment, and innovation, Indian government's is coming up with comprehensive strategies to combat cancer. A press release titled "Towards a Cancer-Free India" revealed that in the Union Budget 2025–26, INR 99,858.56 crore has been allocated to the Ministry of Health and Family Welfare, including INR 3,900.69 crore dedicated specifically to health research. This substantial investment is set to boost cancer diagnostics research, particularly in biomarker discovery and validation, which will drive growth in the cancer biomarkers market. Additionally, the government plans to establish Day Care Cancer Centres in every district hospital, with 200 centers targeted for launch in 2025–26. This move aims to decentralize cancer treatment and improve access to diagnostic services, thereby increasing demand for reliable, efficient biomarker-based testing solutions.
India Cancer Biomarkers Market Trends
4baseCare launched TARGT Indiegene V2, its next-generation comprehensive genomic profiling test for cancer biomarker testing. The assay covers 2,206 genes, including copy-number variations and 299 clinically relevant gene fusions, while applying a biology-first approach based on the Hallmarks of Cancer. The development strengthens India's indigenous precision-oncology capabilities by providing broader molecular characterization within a single test. It can expand demand for genomic biomarker testing among oncology centers seeking actionable information for treatment selection, particularly for patients with complex or advanced cancers.
Shankara Cancer Hospital and Research Centre partnered with 4baseCare to integrate advanced next-generation sequencing (NGS) into routine oncology practice. The hospital upgraded its molecular diagnostics laboratory with a high-throughput NGS platform and adopted 4baseCare's TARGT Indiegene assay, which analyses more than 1,200 cancer-associated genes using DNA and RNA sequencing. The partnership also introduced subsidized access to comprehensive genomic profiling. This development can broaden the use of actionable biomarker testing beyond major metropolitan centers by combining molecular diagnostics infrastructure with more affordable testing, supporting wider adoption of precision oncology in India, thus boosting the demand for India cancer biomarkers.
The Government of Andhra Pradesh partnered with AstraZeneca India to develop an Integrated Genomics Solution Centre in Amaravati as part of a broader precision-oncology ecosystem. The planned centre will provide NGS-based genomic and biomarker testing for lung and breast cancers, while AI-enabled screening tools are planned for government hospitals. The initiative represents an important expansion of biomarker infrastructure within the public healthcare system. By integrating genomic diagnostics with early-detection capabilities, the programme could improve access to molecular testing, support personalized treatment decisions and encourage greater utilization of cancer biomarkers across government healthcare facilities.
Zydus Lifesciences and Apollo Hospitals entered into an MoU to make Guardant Health's Shield Multi-Cancer Detection test available in India. The methylation-based blood test uses a single blood draw to screen for signals associated with 10 cancer types, including colorectal, breast, lung, liver, gastric, ovarian and pancreatic cancers, among others. Apollo Cancer Centres became the first Indian healthcare institution to offer access to the test. The development strengthens the country's liquid-biopsy ecosystem and could stimulate demand for blood-based molecular biomarkers, particularly as healthcare providers explore less-invasive approaches to multi-cancer screening.
Growing Adoption of Comprehensive Genomic Profiling
The cancer biomarker market in India is transitioning from the use of biomarkers one at a time to genomic profiling. Genomic profiling offers a more holistic view because it can be used to determine various genomic changes including mutations, fusions, copy number changes etc. at once, hence minimizing the number of tests that have to be done. There have been findings in cohorts of Indian patients that show the utility of genomic profiling in cancer, where comprehensive genomic profiling has uncovered many more potentially treatable targets than smaller panels. Increasing availability of NGS infrastructure, falling sequencing costs and growing awareness of precision oncology are therefore supporting movement toward broader molecular characterisation before treatment selection, thus driving the growth of the India cancer biomarkers market.
Expansion of Liquid Biopsy Applications
Liquid biopsy has been gaining significance as Indian laboratories and oncologists are looking at ways of getting molecular data in a less invasive manner. The use of ctDNA can help understand mutations in tumours without having to go through a number of tissue biopsies and hence will be significant in helping in the choice of therapy and the monitoring of the disease. Indian studies have also shown the application of NGS through ctDNA in the clinical management of lung cancer patients, thus making it evident that liquid biopsy will move on from being used mainly for research purposes to become clinically significant. As laboratory capabilities improve, liquid biopsy is expected to gain relevance in detecting emerging resistance mutations, monitoring treatment response and identifying molecular changes when obtaining fresh tumour tissue is difficult.
Increasing Role of Population-Specific Genomic Data
The development of cancer biomarkers in India is increasingly influenced by the need for genomic datasets that represent the country's diverse population. Historically, many reference datasets used in precision medicine have been dominated by populations from North America and Europe, potentially limiting the interpretation of variants among Indian patients. Indian research institutions are therefore building locally relevant cancer-genomics resources to identify population-specific molecular patterns. Such datasets can improve biomarker discovery, variant interpretation, and validation of diagnostic assays. Over time, greater availability of Indian genomic information can help laboratories develop testing strategies that are better aligned with the country's distinctive tumour biology and genetic diversity, thus shaping the trends of the India cancer biomarkers market.
Integration of Multi-Omic Biomarker Analysis
Developing cancer biomarkers has been progressing from focusing on DNA mutations to multi-omics data analysis which integrates information from genomics, transcriptomics, proteomics and other omics studies in order to gain a better insight into cancer biology. It would help identify the biomarkers linked with treatment response, disease progression, and resistance mechanisms. The Indian scientific community has been actively participating in the discovery of genomics and proteomics-based biomarkers, and advancements in sequencing and computing technologies have made large data sets easier to analyze. It is especially pertinent to precision oncology because integration of various biological layers could provide clinically important information that would be missed using only one biomarker parameter.
Increasing Emphasis on Biomarker Accessibility and Affordability
The Indian market is witnessing greater emphasis on making advanced biomarker testing accessible beyond premium oncology centres. High testing costs, limited molecular-diagnostics infrastructure and uneven availability of specialised laboratories have historically restricted the use of genomic profiling. Partnerships between hospitals, diagnostic companies and technology providers are increasingly addressing these limitations through local testing infrastructure, subsidized services and decentralized access. The expansion of NGS capabilities into regional healthcare facilities can shorten testing pathways and improve access to actionable molecular information. This trend is particularly important for India because wider affordability and geographical availability are essential for translating precision-oncology technologies into routine clinical practice.
India Cancer Biomarkers Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
- Instruments
- Imaging Instruments
- Pathology-based Instruments
- Biopsy Instruments
- Consumables
- Antibodies
- Kits & Reagents
- Probes
- Bioinformatics Software
Market Breakup by Biomarker
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Genetic Biomarkers
- Proteomic Biomarkers
- Others
Market Breakup by Types of Cancer
- Breast cancer
- Cervical cancer
- Lung cancer
- Prostate cancer
- Colorectal cancer
- Liver cancer
- Others
Market Breakup by Technology
- OMIICS Technologies
- Proteomics
- Genomics
- Others
- Imaging Technologies
- Ultrasound Imaging
- Computed Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Mammography
Market Breakup by Application
- Diagnostics
- Drug Discovery and Development
- Personalized medicine
- Others
Market Breakup by End User
- Hospitals
- Academic and Research Centers
- Diagnostic Laboratories
- Pharmaceutical Companies
- Others
Market Breakup by Region
- North India
- East and Central India
- West India
- South India
India Cancer Biomarkers Market Share
Breast Cancer and Lung Cancer Hold a Substantial Share Based on Segmentation by Type of Cancer
The cancer biomarkers market in India is primarily driven by the high prevalence and mortality rates of specific cancers, with breast, cervical, lung, and oral cancers accounting for the majority of the disease burden. Breast and cervical cancers dominate among women, with one woman dying of cervical cancer every eight minutes and a 50% mortality rate among newly diagnosed breast cancer cases.
In men, lung and oral cavity cancers are among the leading causes of death, largely due to tobacco use, which causes around 2,500 deaths daily. Lung cancer alone accounts for one in five male deaths. These statistics underscore a strong demand for biomarkers for early detection, diagnosis, and personalized treatment, particularly in breast, cervical, and lung cancers.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
India Cancer Biomarkers Market Analysis by Region
The market shows significant regional variation, with the highest growth seen in South and West India due to better healthcare infrastructure, higher awareness, and concentration of advanced diagnostic centers in cities like Bangalore, Chennai, Mumbai, and Pune. South India leads in the adoption of biomarker-based diagnostics, especially for breast and cervical cancers, supported by strong medical research and private healthcare investment. North India, including Delhi NCR and parts of Punjab and Uttar Pradesh, also shows high market potential due to rising cases of lung and oral cancers linked to pollution and tobacco use.
Leading Players in the India Cancer Biomarkers Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, was established in 1896. A global leader in pharmaceuticals and diagnostics, Roche plays a significant role in India’s biomarker market through its subsidiary Roche Diagnostics India. The company offers cutting-edge solutions in oncology, cardiology, and infectious disease biomarkers. With a strong emphasis on personalized healthcare, Roche supports early detection and disease monitoring, enhancing clinical outcomes and research across Indian healthcare institutions and laboratories.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc., based in Waltham, Massachusetts, USA, was founded in 2006. It is a major player in India’s biomarker landscape, offering a wide array of analytical instruments, reagents, and assay technologies. The company supports biomarker discovery and validation in oncology, neurology, and immunology. Through its India operations, Thermo Fisher collaborates with academic, clinical, and pharmaceutical partners to accelerate precision medicine, enabling high-throughput biomarker analysis and molecular diagnostics across the country.
Abbott Laboratories Inc.
Headquartered in Abbott Park, Illinois, USA, Abbott Laboratories was founded in 1888. In India, Abbott is a prominent contributor to the biomarker market through its diagnostics division. The company delivers innovative biomarker-based tests and platforms, particularly in cardiology, infectious diseases, and diabetes management. With robust R&D and local collaborations, Abbott helps enhance diagnostic accuracy and timely treatment, strengthening India's healthcare ecosystem with reliable biomarker-driven insights and expanding access to advanced diagnostic solutions.
Illumina, Inc.
Illumina, Inc., founded in 1998 and headquartered in San Diego, California, is a global leader in genomics. In India, Illumina plays a pivotal role in advancing the biomarker market through its next-generation sequencing (NGS) technologies. These platforms are instrumental in biomarker discovery, especially in oncology and rare genetic disorders. Illumina partners with research institutions and diagnostic labs across India to enable precision medicine, driving innovations in genetic screening, disease prediction, and personalized treatment strategies.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include QIAGEN N.V., PerkinElmer Inc., Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., among others.
Key Questions Answered in the India Cancer Biomarkers Market Report
- What was the India cancer biomarkers market value in 2025?
- What is the India cancer biomarkers market forecast outlook for 2026-2035?
- What are the major factors aiding the India cancer biomarkers market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India cancer biomarkers market trends?
- Which product is expected to dominate the market segment?
- Which biomarker is projected to lead the market segment?
- Which type of cancer is expected to dominate the market segment?
- Which application is expected to lead the market segment?
- Which product is expected to dominate the market segment?
- Who are the key players involved in the India cancer biomarkers market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
More Insight Report:
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Biomarker |
|
| Breakup by Type of Cancer |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
